Dr. Max D. Schlesinger, MD

Dr. Schlesinger practices at Ophthalmic Consultants of Long Island in Mineola, New York.

Dr. Schlesinger's NPI, 1093100786, was assigned on March 31, 2015. Dr. Schlesinger graduated from New York University School of Medicine in 2015. Dr. Schlesinger holds New York license 285869.

Dr. Schlesinger's primary practice is Ophthalmic Consultants of Long Island, at 330 Old Country Rd, Mineola, NY 11501 in Nassau County. The practice phone is (516) 766-2519.

Dr. Schlesinger's primary practice is Ophthalmic Consultants of Long Island in Mineola, New York. Dr. Schlesinger is also affiliated with Westchester Medical Center. The medical group on file is Westchester Medical Center Advanced Physician Services. Dmand AI also links Dr. Schlesinger to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schlesinger practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Schlesinger's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Schlesinger is licensed in New York.

CMS data shows 746 Medicare services from Dr. Schlesinger across 8 procedure codes in 2024, for 123 Medicare patients. Medicare paid $99,998 for them. Every service was in an office.

CMS counts 123 Medicare patients who saw Dr. Schlesinger in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schlesinger's median patient age at 69, with 54% women.

In 2024, Dr. Schlesinger wrote 112 Medicare Part D claims for 44 patients. 62% of them were for generic drugs. CMS names the drug for 53 of them, across 3 drugs with 11 or more claims each, at $1,749 in total drug cost. In 2023, CMS named 25 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Schlesinger for performance year 2024, reported as part of a group. Dr. Schlesinger accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Schlesinger, published from 2012 to 2025. Dr. Schlesinger's most frequent co-authors are Ferhina Sultana Ali, MD, Maria R. Cochran-Perez, MD and Terry F. Davies, MD.

CMS Open Payments shows 37 general payments to Dr. Schlesinger from 14 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 94% of the total. Aerie Pharmaceuticals, Inc. paid the most, $345.

Dr. Schlesinger graduated from New York University School of Medicine in 2015.